Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Gains from Sales and Divestitures: 2020-2022

Historic Gains from Sales and Divestitures for Mirum Pharmaceuticals (MIRM) over the last 3 years, with Dec 2022 value amounting to $122,464.

  • Mirum Pharmaceuticals' Gains from Sales and Divestitures fell 8.33% to $122,464 in Q4 2022 from the same period last year, while for Dec 2022 it was $122,464, marking a year-over-year decrease of 8.33%. This contributed to the annual value of $122,464 for FY2022, which is 8.33% down from last year.
  • Mirum Pharmaceuticals' Gains from Sales and Divestitures amounted to $122,464 in Q4 2022, which was up 22.23% from $100,194 recorded in Q3 2022.
  • Mirum Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $133,593 during Q4 2020, with a 5-year trough of $33,396 in Q1 2021.
  • In the last 3 years, Mirum Pharmaceuticals' Gains from Sales and Divestitures had a median value of $83,494 in 2020 and averaged $82,568.
  • Data for Mirum Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY increase of 0.01% (in 2022) and a maximum YoY decrease of 8.33% (in 2022) over the last 5 years.
  • Mirum Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $133,593 in 2020, then remained steady at $133,593 in 2021, then fell by 8.33% to $122,464 in 2022.
  • Its Gains from Sales and Divestitures stands at $122,464 for Q4 2022, versus $100,194 for Q3 2022 and $66,796 for Q2 2022.